Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 11/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7952917 | 0.93 | HMGCR (0.49) | HMGCR | |
| SCHEMBL20699721 | 0.91 | HMGCR (0.48) | HMGCR | |
| SCHEMBL4451033 | 0.89 | HMGCR (0.48) | HMGCR | |
| SCHEMBL4453080 | 0.89 | HMGCR (0.48) | HMGCR | |
| SCHEMBL20713953 | 0.89 | HMGCR (0.47) | HMGCR | |
| SCHEMBL20713949 | 0.85 | HMGCR (0.44) | HMGCR | |
| Methylamine SCHEMBL3171804 | 0.85 | HMGCR (0.46) | HMGCR | |
| SCHEMBL19231349 | 0.85 | HMGCR (0.53) | HMGCR | |
| SCHEMBL20713950 | 0.84 | HMGCR (0.46) | HMGCR | |
| SCHEMBL3167877 | 0.84 | HMGCR (0.47) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210169838-A1 | Novel class of compounds for the treatment of cardiovascular disease. | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2021-06-10 | — | — | US | disclosed |
| US-20190038588-A1 | NOVEL CLASS OF COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038588-A1 | NOVEL CLASS OF COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | FABP3, TNNI3, TNNT2 | HMGCR 18/4885 |
| US-20210169838-A1 | Novel class of compounds for the treatment of cardiovascular disease. | FABP3, TNNI3, TNNT2 | HMGCR 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.